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Heart failure (HF) is a condition characterized by signs and symptoms mainly attributable 
to reduced forward flow and increased venous congestion. The estimated prevalence in Europe 
(> 900 million people) is at least 15 million patients according to recent European guidelines 
on HF [1]. Despite the initiation of new therapies, the prognosis of patients with HF is still 
incredibly poor: almost half of patients have a life expectancy of less than 4 years [1]. The 
reason for the persisting poor prognosis of patients with HF is not evident, but the changing 
characteristics of patients with HF may be an important aspect of the problem. In comparison 
to patients with HF who were diagnosed in the late 80’s, HF patients now tend to be older 
(Figure 1) and more often female [2].
Furthermore, with the aging HF population, co-morbidities or other organ dysfunction are 
much more frequent, which further complicates treatment and may reduce or obscure the effect 
of HF treatment on mortality and morbidity [3-8]. The life-expectancy of these co-morbidities 
itself could be a limiting factor, which may indicate the need for a shift in focus of targets of 
treatment in HF. In particular renal failure has received increasing attention in the last decade 
[7,9-13]. Interestingly, renal impairment is not only more frequently observed in patients with 
HF who are older and female [14], but the frequency of patients with chronic kidney disease as 
defined by different definitions in large HF trials has risen in the last two decades (Figure 2).
Figure 1. Relationship between year of publication of study and mean age of included patients. Shown are 
HF studies, including registries, clinical trials and observational cohort studies in the period 1985–2008. Included 
are acute as well as chronic heart failure studies, in combination with studies that included left ventricular 
dysfunction after myocardial infarction. Mean age is taken, irrespective of inclusion or exclusion criteria. Size of 
circles is relative to the study size. The solid line represents the fitted regression line, weighted for study size. 
Dashed lines represent 95% confidence intervals [2].
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The kidney is the main organ responsible for water and salt homeostasis, blood pressure 
control and secretion of important hormones for hemodynamic stability. In normal physiologic 
circumstances, the kidney receives approximately 20-25% of the total cardiac output [15]. It 
therefore is the organ that receives the highest blood flow per gram of body weight in the human 
body. The main function of the kidney is usually measured by the glomerular filtration rate 
(GFR). Normally, GFR is maintained constant by renal autoregulatory mechanisms, which are 
capable of maintaining renal blood flow (RBF) by changing vasomotor tone in the efferent and 
afferent renal arteriole, despite changes in systemic blood pressure. In cardiovascular disease 
however, kidney function or GFR is often compromised [16]. In general, renal impairment is 
referred to as any decrease in GFR below normal, but the most used definition is CKD, with 
(estimated) GFR below 60 mL/min/1.73m. The National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative (KDOQI) further classifies different stages from ≥ 90, 60-89, 
30-59, 15-29 and < 15 (or dialysis) mL/min/1.73m. Finally, also the method used to determine 
GFR may influence the definition of renal impairment, as different formulas estimating 
GFR may be biased and imprecise in specific conditions, including HF [17]. Main reasons for 
renal impairment in cardiovascular disease include atherosclerosis, hypertension, endothelial 
dysfunction and inflammation, but many others have been identified or suggested [18-22]. 
Although the pathogenesis of reduced GFR in individual patients may differ, the result is the 
same: reduced GFR is strongly related to increased mortality and morbidity [7,16]. In addition, 
(micro) albuminuria, as a marker of glomerular damage is frequently observed in patients with 
cardiovascular disease, and further adds to the impaired prognosis in these patients [23-25].
Figure 2. Relationship between year of conduction of study and percentage of patients with chronic 
kidney disease. Shown are some key HF studies. The solid line represents the fitted regression line. Image 
obtained from data from original reports of studies mentioned.
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Renal impairment in heart failure
In the spectrum of cardiovascular disease, HF is a particularly important disease with respect 
to renal function and renal function impairment. Renal impairment is frequently observed in 
patients with HF, and has consistently been shown to increase the risk for all-cause mortality 
and HF rehospitalizations [7,11,12,16]. The presence of CKD (as defined as GFR below 60 
mL/min/1.73m2) relates to a strongly increased mortality (Figure 3), while the extent of renal 
impairment as estimated by serum creatinine is also associated with the severity of impaired 
prognosis (Figure 4).
Importantly, not only renal function in patients with chronic HF (CHF) is an important 
mediator of outcome, but also inhospital renal impairment in patients with acute HF (AHF) 
plays an important role [26]. New therapies are emerging specifically targeted at prevention of 
worsening of renal function, or even improvement of GFR to improve subsequent prognosis 
[27]. The striking morbidity associated with a combination of renal impairment and HF may 
mutually influence the disease progression of both diseases.
Figure 3. Forrest plot of relationship between chronic kidney disease and mortality in HF. Shown is risk for 
all-cause mortality of HF patients with CKD versus without CKD. Odds ratio’s were estimated using event rates 
presented in individual studies. Overall odds ratio was estimated using random effects meta-analysis.
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Pathophysiology of renal failure in heart failure
Renal impairment as co-existing in and as a consequence of HF has been recognized as 
early as 1868 [28]. Historically, hemodynamic alterations in HF have been considered the 
cornerstone of the pathophysiology of renal impairment [15,29,30]. Indeed, RBF may decrease 
disproportionate in comparison to reduction in cardiac output [30]. Early studies conducted in 
the first half of the 20th century have investigated the mechanisms responsible for reduction in 
GFR and/or preservation of GFR, which resulted in the discovery of the renal autoregulatory 
mechanisms [31]. Only after the angiotensin II mediated efferent vasoconstriction was 
discovered, angiotensin converting enzyme inhibitors (ACEi) were developed to specifically 
target the autoregulatory response [15,32-37]. In studies in patients with CHF without ACEi, a 
reduction in RBF has been established as the main determinant of a reduction in GFR [29,30]. 
Interestingly, when cardiac index and subsequently RBF decreased, GFR was preserved to 
some extent by increasing the filtration fraction. However, eventually GFR decreases when the 
renal autoregulatory mechanisms are unable to further increase filtration fraction. Whether 
the introduction of ACEi has had a mediating effect on the relationship between RBF and 
GFR is one of the focuses of the present thesis as discussed in chapter 1.
HF is not only characterized by a decreased cardiac output and subsequent decreased organ 
perfusion, but also by increased venous congestion. This was already recognized 100 years 
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Figure 4. Relationship between serum creatinine and annual mortality in published HF studies. Shown 
are HF studies, including registries, clinical trials and observational cohort studies in the period 1985–2008. 
Included are acute as well as chronic heart failure studies, in combination with studies that included left ventricular 
dysfunction after myocardial infarction. Size of circles is relative to the study size. The solid line represents the 
fitted regression line, weighted for study size. Dashed lines represent 95% confidence intervals
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ago, when experimental work in HF animal models was conducted to evaluate the precise 
pathophysiologic link between HF and renal failure [38-40]. Different models were used to 
establish renal failure in these models, including artificially increasing renal venous pressure 
[34,39-41]. In these studies, especially the effect of increasing renal venous pressure (or central 
venous pressure (CVP)) on reducing renal perfusion pressure was observed. However, also 
more structural abnormalities with increasing CVP were studied, which may indicate more 
direct effects on renal function by increased CVP [39,40,42]. In addition, observations made 
in the abdominal compartment syndrome have more recently re-introduced the concept of an 
effect of increased CVP on renal function [43,44]. In HF however, little is known about the 
relationship between CVP and renal function. Therefore, we evaluated the link between CVP 
and RBF with GFR in patients with cardiac dysfunction in chapter 2, and in a more general 
cardiovascular population in chapter 3. Measuring CVP invasively in every patient with HF 
is now considered obsolete, even in patients with AHF [45]. Therefore, we investigated the 
relationship between non-invasively determined symptoms and signs of venous congestion, 
renal function and outcome in a large cohort of patients with CHF in chapter 4.
Changes in renal function in patients with heart failure
Although renal impairment at any point in time has been shown to be related to poor 
prognosis in patients with HF, it may be much more important to know the progression of 
cardiorenal disease. At the present time, little is known about the progression of renal failure 
in patients with HF, but it has been suggested that the (downward) slope of renal function 
over time may be similar to patients with CKD. This would indicate a much steeper decline in 
GFR as compared to the normal population, in which GFR decreases at around 0.5 -1.0 mL/
min/1.73m2 every year [46,47]. Considering the already depressed baseline renal function at 
which patients with HF start of with, this further emphasizes the need for close control of renal 
function in these patients. In addition, recent evidence is accumulating that not only a great 
proportion of patients with HF experience an exceptional fast decline in renal function, but 
also that this occurrence of worsening renal function (WRF) is associated with an unfavorable 
outcome [48,49]. To further address this issue, we have pooled several of the studies examining 
WRF and outcome in patients with HF in chapter 5. Renal function is a dynamic process, and 
GFR may fluctuate over time. Therefore we assessed the relationship between the occurrence of 
WRF at different points in time and the slope of renal function in patients with HF in chapter 
6.
Emerging pathophysiological pathways of the cardiorenal connection in pa-
tients with heart failure
While decreased RBF may be the crucial step in the pathophysiology of decreased GFR in 
HF, the actual mechanisms leading to a reduction in RBF may be more than only a reduction 
in cardiac output. General endothelial dysfunction may have profound effects on renal 
perfusion [50]. Renal artery stenosis, especially in patients with atherosclerotic disease, may 
be found in almost 20% of patients with CHF [51]. A key component is the activation of the 
renin angiotensin system, together with an increase in sympathetic nervous system activation 
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[50]. Adenosine mediated vasoconstriction may be an important mechanism responsible for 
reduced RBF, and now emerges as a possible target for therapy in especially AHF [27]. The 
interrelationship of these different domains and the effect on renal function and outcome is 
outlined in chapter 7.
Finally, decreasing RBF may not only cause a decrease in GFR, but may also trigger more 
general renal hypoxia [52]. This may give rise to problems, especially in regions of the kidney 
that consume the largest amount of oxygen, which are the proximal tubules. In CKD, the final 
common pathway of renal disease is considered to be renal hypoxia [52,53]. This in turn will 
lead to increased interstitial fibrosis and glomerular sclerosis. Urinary tubular marker protein 
concentrations, measured in acute and CKD, have shown a strong increase in these markers 
of tubular dysfunction in response to (acute) renal dysfunction [54-56]. Additionally, their 
urinary concentrations correlated with the extent of tubulointerstitial injury, prognosis and 
response to treatment [54,57]. In CHF however, very little is known about tubulointerstitial 
damage, or tubular dysfunction. Therefore, we investigated the prevalence of tubular damage 
in CHF patients in chapter 8, and extended our investigation to include the relationship with 
prognosis in chapter 9.
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Aims of the thesis
In the last decade, renal impairment in HF has emerged as an important marker for 
prognosis, disease progression, pathophysiology of HF and as target for therapy. In this 
thesis, the underlying pathophysiology of renal impairment in HF, its decline over time, the 
relationship with prognosis, and the importance of  tubular damage and new therapeutic 
targets, were studied.
In PART I, the pathophysiology of renal impairment in HF was investigated. Chapter 1 
focuses on different associations between established risk markers of renal impairment and GFR 
as well as RBF in patients with HF who underwent invasive determination of renal function 
and perfusion. In chapter 2, we addressed the effect of reduced RBF and increased CVP on 
the relationship with GFR in patients with cardiac dysfunction, secondary to pulmonary 
hypertension. We further explored the relationship between CVP and GFR in a more general 
cardiovascular population in chapter 3, while signs of venous congestion, and the relationship 
with prognosis and renal function in patients with HF were the primary focus in chapter 4. 
In PART II, we investigated the decline of renal function and WRF, and the relationship 
with prognosis in patients with HF. Chapter 5 describes a pooled analysis of eight studies 
investigating the relationship between the occurrence of WRF at a given time point and 
prognosis in patients with both chronic and acute HF. To further investigate the effect of WRF 
at different points during and after HF hospitalization, and to investigate the slope of renal 
function over time, we studied these associations in a substudy of the COACH in chapter 6.
PART III focuses on tubular damage and possible new targets for therapy in HF patients 
with renal impairment. In chapter 7 different pathways by which renal failure may initiate a 
worse prognosis are investigated. In the last two chapters, a new entity in patients with HF is 
studied, which consists of the occurrence of tubular damage. Chapter 8 studied the prevalence 
of tubular dysfunction, while in chapter 9 the relationship with prognosis was investigated. 
Finally, in the discussion and future directions the results of the present thesis are discussed 
and put into clinical context. Future perspectives, especially with regards to therapy in patients 
with renal impairment and HF are discussed.
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